Early research shows promising data with potential 20%+ reduction in inflammatory markers, but this remains off-label use
report a decreased risk of RGC in patients on GLP-1 RAs undergoing concurrent EGD and colonoscopy when compared to EGD alone (protection ratio (PR) = 0.25, confidence interval 0.160.39) [16]
[54] The drug decreases mimicks the hormone glucagon-like peptide-1 (GLP-1), an incretin
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability)
The mechanism of action involves binding to GLP-1 receptors found predominantly in pancreatic beta cells, where they enhance glucose-dependent insulin secretion
The action follows disciplinary measures in Kansas, Louisiana, and Ohio, where the company faced fines and licensing sanctions related to pharmacy practice violations and the distribution of compounded drugs